证券代码：603102 证券简称：百合股份 公告编号：2023-042 威海百合生物技术股份有限公司 关于公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 经中国证券监督管理委员会证监许可[2022]36 号文核准，本公司于 2022 年 1 月向社会公开发行人民币普通股（A 股）1,600.00 万股，每股发行价为 42.14 元，募集资金总额为人民币 67,424.00 万元，根据有关规定扣除发行费用 7,180.89 万元后，实际募集资金金额为 60,243.11 万元。该募集资金已于 2022 年 1 月到 账，上述资金到账情况业经容诚会计师事务所容诚验字[2022]251Z0001 号《验资 报告》验证，公司对募集资金采取了专户存储管理。后因证券登记费减免 6.40 万 元，实际发行费用较之前减少 6.40 万元，募集资金净额实际为 60,249.51 万元。 （二）本年度使用金额 ...

证券代码：603102 证券简称：百合股份 公告编号：2023-041 威海百合生物技术股份有限公司 威海百合生物技术股份有限公司（以下简称"公司"）于 2023 年 7 月 29 日向 各位监事发出了召开第四届监事会第四次会议的通知。2023 年 8 月 8 日，第四 届监事会第四次会议以通讯和现场投票相结合的表决方式在公司会议室召开，应 出席本次会议的监事 3 人，实际出席本次会议的监事 3 人，监事会主席刘禄增先 生主持会议，会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的有关规定。 二、监事会会议审议情况 与会监事经认真审议和表决，通过如下决议： （一）审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会认为，董事会编制和审核 2023 年半年度报告及其摘要的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 （二）审议通过了《关于公司 2023 年半年度募集资金存放与实际使用情况 专项报告的议案》 第四届监事会第四次会议决 ...

独立董事关于第四届董事会第五次会议相关事项的 威海百合生物技术股份有限公司 独立意见 根据《上市公司独立董事规则》《上市公司治理准则》《上海证券交易所股 票上市规则》等法律、法规以及《公司章程》和公司《独立董事工作细则》的有 关规定,我们作为威海百合生物技术股份有限公司(以下简称"公司")的独立 董事,本着认真、负责、实事求是的态度,对公司第四届董事会第五次会议相关 事项的独立意见如下: 一、关于公司 2023年半年度募集资金存放与实际使用情况的专项报告的独 立意见 我们认为,《关于公司 2023年半年度募集资金存放与实际使用情况的专项 报告》真实地反映了公司募集资金存放、使用与管理的情况,公司募集资金的存 放和实际使用情况符合《上市公司监管指引第2号 -- 上市公司募集资金管理和 使用的监管要求》《上海证券交易所上市公司自律监管指引第1 号 -- 规范运作》 等有关规定。公司对募集资金进行了专户存储和专项使用,并及时履行了相关信 息披露义务,募集资金实际使用情况与公司信息披露情况不存在差异,不存在募 集资金存放和使用违规的情形。 (以下无正文,转签字页) (本页无正文,为威海百合生物技术股份有限公司独立董事 ...

证券代码：603102 证券简称：百合股份 公告编号：2023-028 威海百合生物技术股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 4 月 18 日（星期二）16:00 前通过公司邮箱 suntongbo@sohu.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 威海百合生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况及利润分配，公司计划于 2023 年 4 月 19 日下午 15:00-16:00 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交 流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果、 财务指标及利润分配的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥231,965,285.09, representing a year-on-year increase of 58.73%[3] - The net profit attributable to shareholders for the same period was ¥44,783,221.82, reflecting a growth of 43.99% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,663,071.25, up by 47.28% year-on-year[3] - The basic earnings per share for Q1 2023 was ¥0.70, an increase of 32.08% from the same period last year[3] - Operating profit for Q1 2023 was ¥51,434,864.07, up 42.5% from ¥36,134,571.23 in the same period last year[16] - Net profit attributable to shareholders for Q1 2023 was ¥44,783,221.82, representing a 43.5% increase from ¥31,101,485.21 in Q1 2022[16] - Basic and diluted earnings per share for Q1 2023 were both ¥0.70, compared to ¥0.53 in Q1 2022[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,691,268,320.85, which is a 1.76% increase from the end of the previous year[3] - As of March 31, 2023, the company's total assets amounted to ¥1,691,268,320.85, an increase from ¥1,661,982,995.88 as of December 31, 2022, reflecting a growth of approximately 1.4%[12] - The company's total current assets reached ¥1,335,435,966.94, compared to ¥1,307,447,191.14 at the end of 2022, indicating an increase of about 2.1%[12] - Total liabilities decreased to ¥224,435,937.28 from ¥239,933,834.13, a reduction of approximately 6.4%[14] - The company's equity attributable to shareholders increased to ¥1,466,832,383.57 from ¥1,422,049,161.75, reflecting a growth of about 3.1%[14] Cash Flow - The cash flow from operating activities showed a net outflow of ¥10,261,019.33, a decrease of 24.10% compared to the previous year[3] - Cash flow from operating activities for Q1 2023 was ¥10,261,019.33, down 24.5% from ¥13,518,587.35 in Q1 2022[19] - The company reported a net cash outflow from investing activities of ¥65,853,894.83 in Q1 2023, compared to a net outflow of ¥13,860,848.35 in Q1 2022[19] - The company experienced a net cash inflow from financing activities of ¥604,672,519.48 in Q1 2023, with no comparable figure reported for Q1 2022[19] Expenses - The company's research and development expenses increased by 41.69%, indicating a rise in investment in innovation[6] - Research and development expenses for Q1 2023 amounted to ¥6,765,422.11, up 41.7% from ¥4,774,889.11 in Q1 2022[15] - The company's financial expenses surged by 184.42%, primarily due to an increase in bank deposit balances and interest income[6] - Total operating costs for Q1 2023 were ¥175,042,448.36, an increase of 61.2% from ¥108,512,966.16 in Q1 2022[15] Accounts Receivable and Payable - The company reported a significant increase in accounts receivable by 41.90%, attributed to revenue growth[6] - Accounts receivable rose to ¥46,607,305.17, up from ¥32,844,069.92, marking an increase of around 42%[12] - The company reported a decrease in accounts payable to ¥94,966,301.36 from ¥98,628,162.51, a decline of approximately 3.4%[13] Other Information - The number of ordinary shareholders at the end of the reporting period was 8,549[8] - The company has not disclosed any new product or technology developments in this quarter[10] - There are no significant mergers or acquisitions reported during this period[10] - The company announced the implementation of new accounting standards starting in 2023, which will affect the financial statements from the beginning of the year[20]

Financial Performance - The company's operating revenue for 2022 was ¥725,326,008.10, representing a 9.59% increase compared to ¥661,874,435.29 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥137,841,124.35, a decrease of 6.89% from ¥148,039,239.10 in 2021[25]. - The net cash flow from operating activities was ¥152,905,236.45, down 9.60% from ¥169,149,696.97 in the previous year[25]. - The total assets at the end of 2022 were ¥1,661,982,995.88, an increase of 81.46% from ¥915,918,074.40 at the end of 2021[25]. - The net assets attributable to shareholders increased by 99.25% to ¥1,422,049,161.75 from ¥713,716,609.84 in 2021[25]. - Basic earnings per share for 2022 were ¥2.20, down 28.57% from ¥3.08 in 2021[26]. - The weighted average return on net assets was 10.47% for 2022, a decrease of 12.63 percentage points from 23.10% in 2021[26]. - The company reported a decrease of 1.16% in net profit after deducting non-recurring gains and losses, totaling ¥132,881,456.99 in 2022[25]. - The total operating revenue for the nutrition and health food segment was approximately ¥719.31 million, with a gross margin of 35.96%[71]. - The company achieved an annual revenue of CNY 725.33 million in 2022, representing a year-on-year increase of 9.59%[66]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 6 RMB per 10 shares, totaling approximately 38.4 million RMB, which represents 27.86% of the net profit attributable to shareholders[5]. - The profit distribution plan is subject to approval by the shareholders' meeting[6]. - The company has a cash dividend policy that mandates a minimum of 10% of distributable profits to be distributed as cash dividends when conditions are met[147]. - The proposed cash dividend for 2022 is 38.4 million yuan, which accounts for 27.86% of the net profit attributable to shareholders[157]. Risk Management - The company has detailed potential risks in the report, advising investors to be cautious[9]. - There are risks related to product quality and food safety, which could impact the company's reputation and sales[114]. - The company faces regulatory risks due to potential changes in food safety laws and regulations that could affect the industry landscape[115]. - The company emphasizes the importance of timely technological advancements to maintain market position and competitive advantage[117]. Corporate Governance - The board of directors and management guarantee the authenticity and completeness of the annual report[8]. - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[4]. - The company has established specialized committees under the board, including audit, nomination, compensation, and strategy committees[138]. - The company did not face any penalties from securities regulatory authorities in the past three years[135]. - The company’s board includes members with diverse backgrounds and experiences, enhancing its governance capabilities[131]. Market Strategy and Product Development - The company aims to enhance its product offerings and expand market presence through new product development and strategic initiatives[16]. - The company is committed to maintaining compliance with various certifications, including FDA and HACCP, to ensure product safety and quality[24]. - The company aims to enhance its core competitiveness and operational efficiency through smart construction and talent development in 2023[35]. - The company plans to strengthen the development of infant supplementary foods, sports nutrition products, and special medical purpose formula foods to diversify its product offerings[40]. - The company has established a comprehensive supplier selection and quality control system to ensure the stability and quality of over 200 raw materials used in production[44]. Research and Development - The company obtained 134 health food filing certificates and was granted 1 invention patent in 2022, enhancing its R&D competitive advantage[33]. - The company’s R&D expenses for the year were CNY 22.51 million, a decrease of 6.45% from the previous year[68]. - The company has 134 R&D personnel, representing 13.05% of the total workforce[85]. - The company is increasing investment in technology research and development to enhance the conversion of research outcomes[113]. Operational Efficiency - The company completed the construction of a digital platform and introduced MES management systems, enhancing operational efficiency[34]. - The new production lines for marine functional beverages and gummy products began operations in 2022, contributing to production efficiency[34]. - The intelligent factory for oral liquids is expected to enhance production capacity and efficiency, contributing to future revenue growth[72]. - The company has increased its investment in IT infrastructure and smart factory construction, enhancing production quality and operational stability through the implementation of a cloud-based MES system[36]. Shareholder Information - The total number of shares held by Liu Xinli, Chairman and General Manager, remained unchanged at 26,198,803 shares, with a pre-tax compensation of 1,947,700 CNY[126]. - The total number of shares held by Liu Luzen, Director and Union Chairman, remained unchanged at 1,710,730 shares, with a pre-tax compensation of 100,000 CNY[126]. - The total number of shares held by Ge Yongle, Director and CFO, remained unchanged at 1,210,726 shares, with a pre-tax compensation of 408,800 CNY[126]. - The total number of shares held by Liu Zhaomin, Supervisor, remained unchanged at 1,936,742 shares, with a pre-tax compensation of 0 CNY[127]. - The total number of shares held by Zheng Zihai, Employee Representative Supervisor, remained unchanged at 1,210,029 shares, with a pre-tax compensation of 79,300 CNY[127]. Social Responsibility and Environmental Impact - The company invested a total of 62.94 million yuan in public welfare projects, including 50 million yuan in donations for public welfare in Rongcheng City[164]. - The company did not establish an environmental protection mechanism and did not invest any funds in environmental protection during the reporting period[162]. - The company did not take any measures to reduce carbon emissions during the reporting period[163]. - The company did not disclose a separate social responsibility or ESG report during the reporting period[164].

证券代码：603102 证券简称：百合股份 公告编号：2022-031 威海百合生物技术股份有限公司 关于参加 2022 山东辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，威海百合生物技术股份有限公司（以下 简称"公司"）将参加由山东证监局指导、山东上市公司协会等单位联合举办的 2022 山东辖区上市公司投资者集体接待日活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录全景网"投资者关系互 动平台"（http://rs.p5w.net/），或关注微信公众号：全景财经，或下载全景路演 APP，参与本次互动交流，活动时间为 2022 年 11 月 16 日（周三）14:00-16:00。 届时公司高管将在线就公司业绩、公司治理、发展战略、经营状况等投资者关心 的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 威海百合生物技术股份有限公司董事会 2022 年 11 月 15 日 ...

威海百合生物技术股份有限公司 2022 年第三季度报告 2022 年第三季度报告 证券代码：603102 证券简称：百合股份 □是 √否 一、 主要财务数据 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 重要内容提示： 第三季度财务报表是否经审计 (一)主要会计数据和财务指标 1 / 18 单位：元 币种：人民币 项目 本报告期 本报告期比上 年同期增减变 动幅度(%) 年初至报告期 末 年初至报告期末 比上年同期增减 变动幅度(%) 营业收入 191,188,302.01 16.75 519,223,878.36 10.47 归属于上市公司股东的 净利润 34,981,203.41 -28.71 106,646,743.71 -9.59 归属于上市公司股东的 扣除非经常 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders for the same period was RMB 20 million, up 10% compared to the previous year[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-over-year growth of 15%[22]. - The company's revenue for the first half of the year reached ¥328,035,576.35, representing a 7.11% increase compared to the same period last year[23]. - Net profit attributable to shareholders was ¥71,665,540.30, up 4.03% year-over-year[23]. - The net profit after deducting non-recurring gains and losses increased by 10.88% to ¥68,329,583.25[23]. - The company has set a future outlook with a revenue target of 2.5 billion RMB for the full year 2022, which would require a 10% growth in the second half[22]. - The company achieved a revenue of 328.04 million RMB, representing a year-on-year growth of 7.11%[55]. - The total profit for the first half of 2022 was CNY 82,891,531.86, up from CNY 79,028,684.93 in the first half of 2021, reflecting a growth of 4.8%[126]. User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching a total of 500,000 users by June 30, 2022[1]. - User data indicates a growing customer base, with a 20% increase in active users compared to the previous year, reaching 500,000 users[22]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[1]. - The company is expanding its market presence, targeting a 25% increase in distribution channels across Asia by the end of 2022[22]. - The company plans to enhance its online sales platform, aiming for a 30% increase in e-commerce revenue by the end of 2022[22]. Research and Development - The company is investing RMB 5 million in R&D for new technologies aimed at enhancing product efficacy[1]. - The company is investing 50 million RMB in research and development for innovative nutritional products over the next two years[22]. - Research and development expenses decreased by 21.81% to 9.98 million RMB, reflecting a strategic focus on optimizing existing products[60]. - The company plans to enhance the development of infant supplementary foods, sports nutrition products, and special medical purpose formula foods[31]. - The company has a strong competitive advantage in R&D, with 25 invention patents and 64 health food approval certificates as of the reporting period[47]. Financial Position and Assets - The company has maintained a strong cash position with cash reserves of RMB 50 million as of June 30, 2022[1]. - The company's total assets grew by 68.79% to ¥1,545,939,184.26 compared to the end of the previous year[23]. - The company's cash and cash equivalents increased by 140.04% to 994.20 million RMB due to funds raised from its initial public offering[62]. - The company's total assets at the end of the first half of 2022 reached CNY 1,355,813,200.34, showing a robust asset base for future growth[140]. - The company's equity attributable to shareholders increased significantly to CNY 1,355,813,200.34 from CNY 713,716,609.84, reflecting a growth of approximately 90%[119]. Corporate Governance and Shareholder Information - The company announced the resignation of independent director Ji Yongsheng and the election of Li Bingsheng as a new independent director[66]. - Liu Luzeng resigned as a non-independent director, while Yao Jianwei was elected as a new non-independent director[66]. - The company confirmed that it is not a key pollutant discharge unit and has no relevant environmental information to disclose[70]. - The company’s actual controller and major shareholders have committed to not transferring their shares for 36 months post-IPO[73]. - Major shareholders, including Liu Xinqiang, are restricted from transferring shares for 36 months post-IPO, while other shareholders have a 12-month restriction[76][77]. Compliance and Legal Matters - The company guarantees that the prospectus for its initial public offering (IPO) does not contain false records, misleading statements, or significant omissions, and assumes joint legal responsibility for its authenticity, accuracy, completeness, and timeliness[85]. - The company will disclose any failure to fulfill commitments in a timely manner and will apologize to shareholders and the public[89]. - The company has not reported any significant changes in its financial condition or operations[102]. - There are no major related party transactions disclosed during the reporting period[103]. - The company has no significant litigation or arbitration matters during the reporting period[102]. Operational Efficiency - The production model combines "stock production" and "production based on sales," allowing for flexible resource allocation to meet customer demands[39]. - The sales model includes contract manufacturing and self-owned brands, with a focus on cash-on-delivery for most customers[40]. - The company has established a comprehensive procurement system to ensure the quality of over 200 raw materials used in production[35]. - Strict quality control measures are implemented for raw materials, including batch testing before production[38]. - The company has established a comprehensive raw material storage management system to ensure compliance with technical standards and requirements[37]. Future Outlook - Future guidance estimates a revenue growth of 20% for the full year 2022, projecting total revenue to reach RMB 220 million[1]. - New product launches are expected to contribute an additional RMB 15 million in revenue for the second half of 2022[1]. - The company plans to continue focusing on capital increases and strategic investments to support future growth initiatives[141]. - The company plans to enhance its product offerings in infant nutrition, sports nutrition, and special medical purpose foods[53]. - The company has initiated a strategic partnership with Mars Health for new product development, launching the "Light Body Nourishing Red Ginseng Iron Gummies"[56].

Financial Performance - The company's revenue for 2021 reached ¥661,874,435.29, representing a 14.45% increase compared to ¥578,287,203.18 in 2020[24]. - Net profit attributable to shareholders was ¥148,039,239.10, up 16.46% from ¥127,115,910.01 in the previous year[24]. - The net cash flow from operating activities was ¥169,149,696.97, reflecting a 12.77% increase from ¥149,997,634.85 in 2020[24]. - Total assets at the end of 2021 amounted to ¥915,918,074.40, a 25.84% increase from ¥727,851,850.89 in 2020[24]. - The company's net assets attributable to shareholders increased by 23.04% to ¥713,716,609.84 from ¥580,077,370.74 in 2020[24]. - Basic earnings per share for 2021 were ¥3.08, a 16.23% increase from ¥2.65 in 2020[25]. - The weighted average return on equity was 23.10%, down 1.15 percentage points from 24.25% in 2020[25]. - The company reported a net profit of ¥134,434,185.38 after deducting non-recurring gains and losses, which is a 14.62% increase from ¥117,291,383.17 in 2020[24]. - The diluted earnings per share also stood at ¥3.08, consistent with the basic earnings per share[25]. - The company achieved an operating revenue of 661.87 million RMB in 2021, representing a year-on-year growth of 14.45%[69]. - The net profit attributable to shareholders reached 148.04 million RMB, with a year-on-year increase of 16.46%[69]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 32 million RMB, which accounts for 21.62% of the net profit attributable to ordinary shareholders[4]. - The company has established a cash dividend policy, ensuring at least 10% of distributable profits are allocated for cash dividends[139]. - For the 2021 fiscal year, the proposed cash dividend is 5 RMB per 10 shares, pending approval from the shareholders' meeting[139]. - The cash dividend distribution plan aligns with the company's commitment to return at least 10% of distributable profits to shareholders annually, as per the A-share listing regulations[142]. Research and Development - The company's R&D investment in 2021 was 24.06 million yuan, accounting for 3.64% of operating income, representing a 15.98% increase from the previous year[34]. - The company holds 25 invention patents and 71 health food approval certificates, indicating strong R&D capabilities[59]. - The number of R&D personnel is 133, accounting for 13.50% of the total workforce, with 8 holding master's degrees and 41 holding bachelor's degrees[83]. - Research and development expenses amounted to 24,059,232.88 yuan, representing 3.64% of total operating revenue, with a year-on-year increase of 15.98%[82]. Market and Product Development - The company aims to enhance its product structure by developing infant supplementary foods, sports nutrition products, and specialized medical formula foods[40]. - The company plans to enhance the development of infant supplementary foods and sports nutrition products to strengthen its competitive advantage[65]. - The company plans to establish regional marketing centers in key cities across the country in 2022 to deepen customer demand and enhance service capabilities[35]. - The company aims to accelerate the development of its international market while expanding its domestic market presence in 2022[35]. - The company focuses on new product development and technological innovation to enhance competitiveness and adapt to market needs[36]. Corporate Governance - The board of directors guarantees the authenticity, accuracy, and completeness of the annual report[9]. - The company has implemented measures to ensure compliance with corporate governance standards, aligning with the Company Law and relevant regulations[119]. - The total pre-tax remuneration for the board members and senior management amounted to CNY 7.95 million in 2021, with no changes in shareholding during the reporting period[122]. - The company has a compensation and assessment committee responsible for formulating and reviewing the compensation policies for directors and senior management[126]. - The company has maintained effective internal controls over financial and non-financial reporting, with no significant deficiencies reported[148]. Risks and Challenges - The company has detailed potential risks in the report, urging investors to be cautious[10]. - The company faces risks related to product quality and food safety, which could impact its reputation and sales if not managed properly[109]. - Regulatory changes in food safety laws may significantly affect the long-term development and competitive landscape of the health food industry[110]. - The ongoing COVID-19 pandemic has posed challenges to the company's operations, affecting procurement, production, and sales channels[113]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 46, compared to 11,251 at the end of the previous month before the annual report disclosure[192]. - The top shareholder, Liu Xinli, holds 26,198,803 shares, representing 40.94% of the total shares[195]. - The second largest shareholder, Guangfa Xinde Investment Management Co., Ltd., holds 2,500,000 shares, accounting for 3.91%[195]. - Liu Xinli's shares are subject to a lock-up period until January 26, 2025, while Guangfa Xinde's shares are locked until January 26, 2023[197]. Operational Highlights - The company has established a comprehensive production capability for various dosage forms, including soft capsules, hard capsules, tablets, powders, oral liquids, and bottled drinks[40]. - The company has a production capacity exceeding 3.7 billion units per year, showcasing its scale production advantage[60]. - The company has a well-established marketing network covering over 30 provinces and regions in China, and its products are sold in more than 70 countries[68]. - The company operates in the nutrition and health food industry, benefiting from national policies promoting health and nutrition, which create a favorable environment for growth[39].